The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center
| Autor: | M. Tampaki, M. Skondra, Dimitrios G. Pectasides, Sofia Adamidi, Alexandra Alexopoulou, John Koskinas, Spilios Manolakopoulos, Melanie Deutsch |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty HBsAg Exacerbation medicine.medical_treatment Organophosphonates Context (language use) Antiviral Agents Gastroenterology Antibodies Monoclonal Murine-Derived Immunocompromised Host Liver disease Internal medicine Internal Medicine medicine Humans Immunologic Factors Decompensation Seroconversion Tenofovir Aged Aged 80 and over business.industry Adenine Lymphoma Non-Hodgkin virus diseases Immunosuppression Middle Aged Hepatitis B medicine.disease Leukemia Lymphocytic Chronic B-Cell digestive system diseases Immunology Female Virus Activation Liver function Rituximab business |
| Zdroj: | European Journal of Internal Medicine. 25:768-771 |
| ISSN: | 0953-6205 |
| DOI: | 10.1016/j.ejim.2014.06.028 |
| Popis: | Introduction/aim Patients who present HBV reactivation during immunosuppressive treatment are prone to develop life threatening decompensation of the liver function, therefore prophylaxis and treatment are strongly recommended. So far there are no data regarding the role of tenofovir in this context. Therefore, the aim of our study was to describe our “real life” experience with the use of tenofovir (TDF) in patients who underwent immunosuppressive treatment. Results 38 patients with immunosuppression received antiviral treatment with tenofovir (25 patients as prophylaxis and 13 patients as treatment of HBV reactivation). In all 25 patients in whom prophylactic treatment with tenofovir was administered no HBV flare occurred during immunosuppression and the levels of serum HBV-DNA became or remained undetectable during the follow up period (mean follow up 17.2 months, range 6–54). One patient experienced HBsAg seroconversion. In the 13 patients who exhibited HBV reactivation TDF treatment resulted in complete biochemical and virological response within 6 months except two patients with high pretreatment HBV-DNA levels who became HBV-DNA negative at 9 months. No exacerbation of liver disease or liver related death has been observed. One patient who presented with decompensated cirrhosis during HBV reactivation returned into a compensated state after treatment. No side effects of tenofovir have been documented. Conclusion Tenofovir seems to be highly effective and safe in the prophylaxis and rescue treatment of HBV reactivation in patients who receive immunosuppression therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect